Cost-effectiveness of transient elastography for liver fibrosis screening in Thai patients with diabetes mellitus

doi:10.3748/wjg.v31.i32.110333

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 31, Issue 32

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Supplementary Materials of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (4)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-3) series, Tables (1-3) series.

Item

Count

PDF

HTML

Figures (1-3)

Tables (1-3)

Sum=4

Aug 28, 2025 (publication date) through Aug 27, 2025

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Prospective Study

World J Gastroenterol. Aug 28, 2025; 31(32): 110333
Published online Aug 28, 2025. doi: 10.3748/wjg.v31.i32.110333

Table 2 Cost-utility analysis outcomes, screening age at 50 years

Outcome	No screening	FIB-4 + TE	SAFE + TE	TE alone
Life expectancy (years)	25.30	25.33	25.33	25.34
Total lifetime cost, THB (USD)	198681.9 (5735.72)	199481.6 (5758.8)	199883.2 (5770.4)	200402.6 (5785.4)
Total QALYs	12.788	12.798	12.803	12.805
Compared to no screening
Incremental cost, THB (USD)		799.7 (23.1)	1201.3 (34.7)	1720.7 (49.7)
Incremental QALYs		0.011	0.015	0.017
ICER, THB (USD) per QALY gained		75961.0 (2192.9)	80384.5 (2320.6)	98964.5 (2857.0)
Interpretation		Cost-effective¹	Cost-effective¹	Cost-effective¹
Extended dominance analysis
Incremental cost, THB (USD)		799.7 (23.1)	401.6 (11.6)	519.3 (15.0)
Incremental QALYs		0.011	0.004	0.002
ICER, THB (USD) per QALY gained		75961.0 (2192.9)	90927.9 (2625.0)	212678.2 (6139.8)
Interpretation		Cost-effective¹	Cost-effective²	Not cost-effective³

¹Compared to no screening.

²Compared to fibrosis-4 index + transient elastography.

³Compared to steatosis-associated fibrosis estimator score + transient elastography.

FIB-4: Fibrosis-4 index; ICER: Incremental cost-effectiveness ratio; QALY: Quality-adjusted life-year; SAFE: Steatosis-associated fibrosis estimator score; TE: Transient elastography; THB: Thai baht; USD: United States dollar.

Citation: Kositamongkol C, Tantiyavarong P, Ratanatawan A, Sripongpun P, Mahawithitwong P, Kositamongkol P, Saokaew S, Phisalprapa P. Cost-effectiveness of transient elastography for liver fibrosis screening in Thai patients with diabetes mellitus. World J Gastroenterol 2025; 31(32): 110333
URL: https://www.wjgnet.com/1007-9327/full/v31/i32/110333.htm
DOI: https://dx.doi.org/10.3748/wjg.v31.i32.110333